Clinical Trial Update: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fixed-dose Ledipasvir/Sofosbuvir for 12 or 24 weeks in adults with Hepatitis C infection and sickle cell disease; results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Sickle Cell Disease

Drugs mentioned

• Ledipasvir/Sofosbuvir fixed-dose combination (Ledipasvir + Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-05-25